SCHEMBL4437175

SCHEMBL4437175

Cc1cc(OCc2ccccc2)c(OCc2ccccc2)cc1C(=O)Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 2/20 0.52
RXRB P28702 2/20 0.52
RXRG P48443 1/20 0.52
MCL1 Q07820 1/20 0.52
FFAR4 Q5NUL3 1/20 0.51
MAPT P10636 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
SMPD1 P17405 1/20 0.49
HDAC1 Q13547 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
MAOB P27338 1/20 0.49
GLRA1 P23415 1/20 0.48
MAPK1 P28482 1/20 0.47
HPGD P15428 2/20 0.47
PTGER1 P34995 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL590872 0.89 MCL1 (0.48) RXRARXRBRXRGMCL1FFAR4
SCHEMBL3112448 0.88 RXRA (0.59) RXRARXRBRXRGMCL1FFAR4
SCHEMBL12659976 0.86 GLRA1 (0.57) RXRARXRBRXRGMCL1FFAR4
SCHEMBL21327204 0.84 MCL1 (0.54) RXRARXRBRXRGMCL1FFAR4
SCHEMBL24983814 0.84 ALDH1A1 (0.54) RXRARXRBRXRGMCL1FFAR4
SCHEMBL7825765 0.82 CTSV (0.58) RXRARXRBRXRGMCL1SMN1; SMN2
SCHEMBL15080744 0.81 SMN1; SMN2 (0.56) RXRARXRBRXRGMAPTTDP1
SCHEMBL71526 0.81 RXRA (0.58) RXRARXRBRXRGMCL1FFAR4
SCHEMBL21327456 0.81 LRRK2 (0.57) MCL1FFAR4MAPTTDP1L3MBTL1
SCHEMBL2327231 0.81 MAOB (0.57) MCL1L3MBTL1SMN1; SMN2MAOBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108101870-B Preparation method of active ingredient for selectively treating glaucoma and related salt thereof 盐城师范学院 2020-03-06 CN disclosed
EP-2620429-A1 Hydroxylamine compounds and methods of their use Colby Pharmaceutical Company (US) 2013-07-31 EP disclosed
EP-2125716-A2 HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE Othera Holding, Inc. (US) 2009-12-02 EP disclosed
EP-2120942-A2 DRUG RESISTANCE REVERSAL IN NEOPLASTIC DISEASE Othera Holding, Inc. (US) 2009-11-25 EP disclosed
US-20080280890-A1 HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE COLBY PHARMACEUTICAL COMPANY 2008-11-13 US disclosed
WO-2008103613-A2 HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE OTHERA HOLDING, INC. (US) 2008-08-28 WO disclosed
US-20080200405-A1 Drug Resistance Reversal In Neoplastic Disease COLBY PHARMACEUTICAL COMPANY 2008-08-21 US disclosed
WO-2008101195-A2 DRUG RESISTANCE REVERSAL IN NEOPLASTIC DISEASE OTHERA HOLDING, INC. (US) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280890-A1 HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE HDGF, HMOX1, HMOX2 RXRA 2626/4885RXRB 2241/4885RXRG 2353/4885
US-20080200405-A1 Drug Resistance Reversal In Neoplastic Disease VHL, ABCC1, SLC11A2 RXRA 1018/4885RXRB 1210/4885RXRG 1125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.